Allogene Therapeutics Advances in CAR T Cell Therapy for Autoimmune Diseases
Intellectia.AI2024-09-27
Allogene Therapeutics Advances in CAR T Cell Therapy for Autoimmune Diseases
Introduction
Allogene Therapeutics, a leading biotechnology company in South San Francisco, is making significant strides in the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products targeting cancer and autoimmune diseases. The company is set to present its latest research findings at the American College of Rheumatology's upcoming event.
Event Details
- Researcher: Kristen Zhang, Research Scientist, Allogene Therapeutics
- Abstract Number: 1841
- Session: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
- Date and Time: Monday, November 18, 10:30 a.m-12:30 p.m. ET
The abstract is available on the American College of Rheumatology's website.
Research and Development Plans
Allogene plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the first quarter of 2025. The company aims to achieve proof-of-concept by the end of 2025, marking a pivotal step in their mission to advance CAR T cell therapies for autoimmune diseases.
About Allogene Therapeutics
Allogene Therapeutics is at the forefront of developing "off-the-shelf" CAR T cell products. These innovations promise to provide more reliable and scalable cell therapy solutions, enhancing accessibility for patients in need. The management team, with extensive experience in cell therapy, is dedicated to delivering on-demand treatments that meet the specific needs of various patient populations.
Forward-Looking Statements
This press release includes forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including the timing of regulatory filings, the success of clinical trials, and the potential for AlloCAR T products to treat autoimmune diseases effectively.
Factors that could cause actual results to differ materially include challenges in clinical development, regulatory approvals, and manufacturing processes. For more detailed information, refer to Allogene's SEC filings.
Contact Information
Christine Cassiano
- EVP, Chief Corporate Affairs & Brand Strategy Officer
- Email: Christine.Cassiano@allogene.com
Leslie Bryant
- Email: Leslie.Bryant@allogene.com
Madeleine Goldstein
For more information about Allogene Therapeutics and their innovative therapies, please visit www.allogene.com and follow them on X (formerly Twitter) and LinkedIn.
Share